Todd Campbell

Todd Campbell


Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles


Here's Why Dynavax Is Surging 6.1% Today

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.


Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.


Why InMode Shares Are Soaring 13.7% Today

The medical device maker's boosting its second-quarter guidance.


Here's Why Retractable Technologies Is Skyrocketing 22% Today

The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.


GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.


Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.


Why Bellus Health Stock Tanked 69.2% Today

The company's lead drug has failed a phase 2 trial.


Why MEI Pharma Is Tanking 15.3% Today

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.


Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Pfizer released intriguing data regarding its own COVID-19 vaccine.


Why Translate Bio Crashed 21% Today

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.


uniQure Inks $2 Billion Licensing Deal With CSL Behring

Agreement licenses the rights for a promising hemophilia B gene therapy.


Sanofi's Cost-Cutting Could Mean Big Job Losses

The company's management is considering a restructuring that may eliminate many positions.


EU Experts Recommend Approval of Gilead's COVID-19 Drug

A key advisory team has given remdesivir a thumbs up, clearing the way to an official green light for its use in Europe.


Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma

The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.


Biogen Loses Patent Case Over Its Best-Selling Drug

A judge has ruled in favor of Mylan's challenge to Tecfidera's patent protection.


Why Iveric Bio Is Skyrocketing 24% Today

An upsized public offering has investors increasingly confident about its prospects.


Why Pfizer's Shares Are Slipping 7.6% Today

The biopharma giant reported disappointing late-stage trial results for one of its best-selling medicines.


Dynavax Stock Soars 26.4% Today on COVID-19 Vaccine Hopes

The company's vaccine partner made positive comments about its progress today.


Here's Why MacroGenics Is Tumbling 17.3% Today

Traders are exiting the stock as the ASCO 2020 conference gets underway.


Why Harley-Davidson's Shares Tumbled 5% This Morning

Analyst comments in Barron's are weighing on the motorcycle company today.